Aurinia Pharmaceuticals Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Total Revenue $173k
$420k +142.77%
$463k +10.24%
$318k -31.32%
$50.1m +15660.38%
$45.6m -9.00%
$134.0m +193.89%
$175.5m +30.95%
$235.1m +33.97%
$283.1m +20.38%
$311.5m +10.05%
Revenue From Interest $27k $1.0m $2.2m $2.7m
Cost of Goods and Services Sold $0 $0 $1.1m
$5.7m +419.16%
$14.1m +149.79%
$28.2m +99.66%
$32.7m +15.64%
$30.0m -8.05%
Gross Profit (Calculated) $318k
$50.1m +15660.38%
$44.5m -11.18%
$128.4m +188.37%
$161.4m +25.71%
$206.9m +28.21%
$250.4m +21.03%
Research and Development Expense $14.5m $33.9m $41.4m $52.9m $50.3m $51.1m $45.0m $49.6m $20.8m $32.5m $39.9m
Selling, General and Administrative Expense $171.4m $196.4m $195.0m $101.0m
Amortization of Intangible Assets $1.5m $1.4m $1.5m $1.4m $1.3m $2.1m $2.1m $1.7m $900k $800k
Restructuring Costs $23.1m $1.6m
Operating Expenses $154.4m $239.8m $178.1m $160.8m
Other Operating Income Expense ($2.2m) $195k $2.1m ($9.0m)
Operating Income (Loss) ($25.0m)
($46.9m) -87.27%
($54.1m) -15.42%
($85.2m) -57.58%
($104.3m) ($180.7m) ($111.5m) ($91.7m) ($4.7m) $104.9m
$150.7m +43.69%
Other Operating Income (Expense), Net $6.8m ($574k) $1.5m ($8.4m) $4.3m ($9.5m)
Interest Expense $39k $2.8m $4.1m
Interest Income, Other $1.5m $529k $13.7m
Interest Expense (non-operating) $4.8m $4.3m $4.1m
Interest Income (Expense), Nonoperating, Net $5.1m $17.0m $13.7m
Income (Loss) from Continuing Operations before Income Taxes, Domestic $25.0m $46.9m $54.1m $85.2m ($61.0m) ($180.4m) ($112.4m) ($90.2m) ($8.4m) $103.9m $160.4m
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $25.0m $46.9m $54.1m $85.2m ($102.8m) ($180.2m) ($106.4m) ($77.5m) $7.4m $114.2m $160.4m
Income Tax Expense (Benefit) $0 $0 $73k $144k ($94k) $760k $1.8m $551k $1.7m ($173.0m) ($153.8m)
Net Income (Loss) Attributable to Parent ($25.0m)
($46.9m) -87.27%
($64.0m) -36.65%
($123.7m) -93.14%
($102.7m) +16.99%
($181.0m) -76.24%
($108.2m) +40.22%
($78.0m) +27.88%
$5.8m +107.37%
$287.2m +4893.08%
$314.1m +9.37%
Earnings Per Share, Basic ($0.66) ($0.92) ($0.76) ($1.33) ($1.40) ($0.76) ($0.54) $0.04 $2.14 $2.36
Earnings Per Share, Diluted ($0.66) ($0.92) ($0.76) ($1.33) ($1.40) ($0.76) ($0.54) $0.04 $2.07 $2.28
Weighted Average Number of Shares Outstanding, Basic 141.9m 143.2m 143.1m 134.4m 131.5m
Weighted Average Number of Shares Outstanding, Diluted 141.9m 143.2m 146.2m 138.7m 136.4m
Additional Financial Items
Costs and Expenses $226.3m $245.5m $267.2m $239.8m $178.1m
Depreciation Right of Use Assets $124k
Expense From Share-Based Payment Transactions With Employees $4.2m $6.9m $7.4m
Expense Relating To Short-Term Leases For Which Recognition Exemption Has Been Used $67k
Expense Relating To Variable Lease Payments Not Included In Measurement Of Lease Liabilities $79k
Finance Income $27k $702k $2.2m
Professional Fees Expense $1.7m $2.1m $4.2m $4.7m
Profit Loss Before Tax ($64.0m) ($123.7m)
Profit Loss From Operating Activities ($25.0m) ($46.9m) ($54.1m) ($85.2m) ($104.3m) ($180.7m) ($111.5m) ($91.7m) ($4.7m) $104.9m